Thanks To A New Patent, CB Therapeutics Now Owns A Production Process In The Psychedelic Medicine Industry
CB Therapeutics has been developing standardized biotechnological processes for generating natural compounds and their analogs for clinical research in psychedelic medicine, cannabinoid-based medicines, and food technologies since its foundation.
FREMONT, CA: Psychedelics (serotonergic hallucinogens) are highly potent psychoactive chemicals that alter perception and emotion while also affecting various cognitive processes. They're generally medically safe and don't cause addiction or dependence.
CB Therapeutics, focused on using cellular agriculture to produce environmentally friendly products for human health, has received a new patent covering the use of microorganisms to produce tryptamines and analogs, such as psilocybin and other molecules found in "magic" mushrooms. The patent is another step forward in the Company's quest to develop safe, long-lasting, and scalable molecules for various sectors, researchers, and physicians.
CB Therapeutics, a biotechnology and precision fermentation company, now owns a production procedure that is the future of the psychedelic medication market, thanks to this patent. Almost all other techniques of producing these compounds are either expensive, time-consuming, or have considerable volumes of hazardous waste, CO2, and other environmental consequences.
The cellular agriculture platform developed by CB Therapeutics allows for converting low-cost feedstocks into high-value chemicals. The outcome is a scalable and environmentally conscientious supply chain powered by precise fermentation, which is the way of the future for a variety of products and therapies, including psychedelic medicine.
While patents are a source of contention in regulated markets, they are necessary for small, innovative businesses. They safeguard critical intellectual property, allowing smaller enterprises to collaborate with larger organizations, such as CB Therapeutics' recent agreement with atai Life Sciences to create TryptageniX. Facilitating this kind of collaboration could help diversify service offerings in the psychedelic sector.
The CB Therapeutics team of researchers, businesspeople, and renowned advisory board members are optimistic that this will improve the standardization of environmentally conscious research into items for human health, such as foods, cannabinoids, and psychedelic medicines. Furthermore, when ethical considerations are taken into account, this invention will lead to novel compounds and therapies faster and less expensive than those currently available, benefiting the hundreds of millions of people worldwide who suffer from mental diseases.
By Leni Kaufman, VP & CIO, Newport News Shipbuilding
By George Evans, CIO, Singing River Health System
By John Kamin, EVP and CIO, Old National Bancorp
By Elliot Garbus, VP-IoT Solutions Group & GM-Automotive...
By Gregory Morrison, SVP & CIO, Cox Enterprises
By Alberto Ruocco, CIO, American Electric Power
By Sam Lamonica, CIO & VP Information Systems, Rosendin...
By Sergey Cherkasov, CIO, PhosAgro
By Pascal Becotte, MD-Global Supply Chain Practice for the...
By Stephen Caulfield, Executive Director, Global Field...
By Shamim Mohammad, SVP & CIO, CarMax
By Ronald Seymore, Managing Director, Enterprise Performance...
By Brad Bodell, SVP and CIO, CNO Financial Group, Inc.
By Jim Whitehurst, CEO, Red Hat
By Clark Golestani, EVP and CIO, Merck
By Scott Craig, Vice President of Product Marketing, Lexmark...
By Dave Kipe, SVP, Global Operations, Scholastic Inc.
By Meerah Rajavel, CIO, Forcepoint
By Amit Bahree, Executive, Global Technology and Innovation,...
By Greg Tacchetti, CIO, State Auto Insurance